Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics to Present at Upcoming Conferences
April 05, 2022 08:00 ET | Achilles Therapeutics PLC
LONDON, April 05, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting
April 04, 2022 08:00 ET | Achilles Therapeutics PLC
- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder - - Panel will discuss how TRACERx real-world data enable Achilles’ AI-powered PELEUS...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 08, 2022 08:00 ET | Achilles Therapeutics PLC
LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights
March 01, 2022 07:02 ET | Achilles Therapeutics PLC
- Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 - - Strong cash position of $266 million supports clinical development and...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.
February 07, 2022 07:30 ET | Achilles Therapeutics PLC
LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Provides Business Update and Outlook for 2022
January 13, 2022 07:30 ET | Achilles Therapeutics PLC
LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
December 21, 2021 08:00 ET | Achilles Therapeutics PLC
LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
December 20, 2021 08:00 ET | Achilles Therapeutics PLC
LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
December 09, 2021 07:00 ET | Achilles Therapeutics PLC
-Over 10-fold dose increase at GMP scale with VELOS™ Process 2 manufacturing- -cNeT maintain CD4+ and CD8+ T cell subsets with a highly potent polyclonal phenotype- -Dosing of patients with...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing
November 12, 2021 07:00 ET | Achilles Therapeutics PLC
LONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...